RxDoctor Payments Data

Bret Williams

Optometrist · Meridian, IDNPI 1528003589

Payments from drug & device makers

$1,594in general payments, 2019–2025

Across 64 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$521
  • Alcon$296
  • Bausch & Lomb Americas Inc.$252
  • AbbVie$175
  • Shire North American Group Inc$118
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$70
  • plus $162 from 5 others

What the payments were for

  • Food & beverage$1,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,594 in reported general payments places this provider in the 75th percentile of 304 optometrist providers in Idaho.

See all optometrist providers in Idaho

Medicare billing

Part B allowed, 2024
$101,542
Medicare patients
565
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine42$51,783
XiidraLifitegrast11$13,814
Cyclosporine11$7,474
SimbrinzaBrinzolamide/Brimonidine Tart19$6,690
Latanoprost217$2,154
Brimonidine Tartrate31$814
Dorzolamide Hcl52$770
MoxifloxacinMoxifloxacin Hcl17$737
Prednisolone Acetate20$493
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$473
Timolol Maleate38$264
ErythromycinErythromycin Base17$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$175$51,78342 claims
Bausch & Lomb Americas Inc.Xiidra$252$13,81411 claims
AlconSimbrinza$296$6,69019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 304 optometrist providers in Idaho.

Other optometrist in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →